The U.S. Food and Drug Administration is in charge of regulating the CBD products produced and sold on American soil. Companies like Treat CBD Brand didn’t have those problem. Part of this mandate includes them conducting sample studies with a focus on understanding if CBD companies are mislabeling their products. To that end a report was sent by the FDA, just this week, to the appropriations committees of the U.S. House of Representatives and Senate. FDA CBD Warning Letters were sent out. The title of the report was, “Warning Letters and Test Results for Cannabidiol-Related Products”

Top FDA CBD Warning Letters: 

The sample testing shows that 59% of the CBD products sampled had much less CBD than advertised, additionally there were other samples showing a drastically higher amount of CBD than advertised. This is particularly bad for the industry because concerns over CBD safety are stopping the FDA from approving the free commerce of CBD products in the U.S.

In other words, the lack of honesty and transparency being shown by CBD companies currently is stopping the development and implementation of regulatory framework for CBD. Full transparency, a marketplace with an ethical foundation, and enough data to back them up are all that will allow the FDA to verify its safety. And those regulations will enable the marketplace to expand exponentially. One can only hope that the entrepreneurs impacted by this are taking note.